Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment

Goldman, B. D.

doi:10.1001/archderm.129.9.1166

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although skin biopsy is the direct assessment, this can not be done so often. The levels of sIL‐2R appear to correlate with the clinical status of patients with advanced CTCL 3 . We confirmed that the serum sIL‐2R levels of patients with PVA decreased after NB‐UVB therapy (Fig.…”

Section: Casesupporting

confidence: 77%

Narrow‐band ultraviolet B decreases serum interleukin‐2 receptor levels in patients with poikiloderma vasculare atrophicans

Nakai

Yoneda

Moriue

et al. 2009

Acad Dermatol Venereol

View full text Add to dashboard Cite

peripheral nerve sheath tumours, smooth muscle tumours, spindle cell lipoma, haemangiopericytoma and solitary cutaneous adult myofibroma.At present, the use of immunohistochemical markers is critical for the accurate classification of these tumours. SFTs are typically non-immunoreactive for S-100, keratin, actin, desmin, factor VIII related antigen, CD68, type IV collagen and epithelial membrane antigen. 2 Recent immunohistochemical and ultrastructural studies have shown that such tumours display the features of relative undifferentiated, mesenchymal cells with no evidence of mesothelial diferentiation. 3 These cells, known as dendritic interstitial cells, are characterized for their fibroblast-like features and CD34 positivity, and have been thought to represent fibroblastic precursors elements involved in antigen presentation within connective tissue. 3 Unfortunately, the CD34 positivity is not entirely specific for this entity as a number of other superficial soft tissue lesions, such as dermatofibrosarcoma protuberans, neurofibroma, schwannoma and spindle cell lipoma may also show immunoreactivity with this marker. 3 Therefore, CD34 is a highly sensitive, but non-specific marker for SFT. Recent investigations have shown that expression of the oncoprotein bcl-2, one of the many molecules that regulate apoptosis, is strongly expressed in SFT, whereas dermatofibroma and smooth muscle tumours are negative for this oncoprotein. In dermatofibroma protuberans and neurofibroma, the expression of bcl-2 is variable. Thus, bcl-2 protein expression can be used to fortalice, together with CD34 positivity, the diagnosis of SFT. 3 The cells of SFT also immunostain for CD99. 4 The clinical behaviour of SFT is unpredictable; therefore, complete excision and long-term follow-up should be always performed. 1 References1 Chang SE, Bae GY, Choi JH et al. Cutaneous solitary fibrous tumour with myxoid stroma. Br J Dermatol 2002; 147: 1267-1269. 2 Cowper SE, Kilpatrick T, Proper S, Morgan MB. Solitary fibrous tumor of the skin. Am J Dermatopathol 1999; 21: 213-219. 3 Hardisson D, Cuevas-Santos J, Contreras F. Solitary fibrous tumor of the skin. J Am Acad Dermatol 2002; 46: S37-S40. 4 Mahmood MN, Salama ME, Chaffins M et al. Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotipic expression for O13 (CD99) and CD34.In summary, sIL-2R could be a good marker when treating PVA with NB-UVB therapy.

show abstract

Section: Casesupporting

confidence: 77%

Narrow‐band ultraviolet B decreases serum interleukin‐2 receptor levels in patients with poikiloderma vasculare atrophicans

Nakai

Yoneda

Moriue

et al. 2009

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…We [5][6][7][8][9][10][11][12][13] and other researchers [14][15][16][17][18][19][20][21][22] have shown that serum cytokine levels in tumor patients correlate to clinical parameters.…”

Section: Introductionmentioning

confidence: 94%

Peripheral Blood Immunological Parameters for Use as Markers of Pre-invasive to Invasive Colorectal Cancer

Berghella

Contasta²,

Pellegrini³

et al. 2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

In cancer, the extent to which the disease has spread is probably the most important factor in determining patient prognosis. Hence practical and non-invasive methods are needed to identify disease stage. In a previous paper we showed how diagnostic and prognostic indices for disease progression could be defined by evaluating parameters in peripheral blood. The aim of this study was to identify further serum parameters that could be used. Serum levels of interferon (IFN) gamma, interleukin (IL)4, IL8, IL7, IL1 beta, tumor necrosis factor (TNF) alpha, granulocyte macrophage-colony stimulating factor (GM-CSF), soluble (s) IL2 receptor (R) and sIL6R were studied but only levels of IL4, sIL2R, IL8 and IL7 were found to be significant and would therefore be of use in defining diagnostic and prognostic indices for disease progression. In further detail, our results indicate that when serum levels of sIL2R < 522 U/ml, IL4 < 159 pg/ml and IL8 > 339 pg/ml there is a 95% probability that the disease is in stage I or II where there is no infiltration of lymph nodes; when serum levels of sIL2R > or = 522 Ug/ml, 159 pg/ml < or = IL4 < or = 319 pg/ml, and IL7 < 54 pg/ml, there is a 95% probability that the disease is in stage III and the tumor has invaded the lymph nodes; when the serum levels of IL4 > or = 431 pg/ml and IL7 > or = 54 pg/ml, there is a 95% probability that the disease is in stage IV and there is metastasis.

show abstract

“…Surrogate markers were evaluated during the studies (Table II) and included the soluble IL-2 receptor level, flow cytometry determinations of the absolute numbers of CD4 and CD8 cells, and populations of CD4+/CD7) and CD4+/CD26) cells, quantitative serum immunoglobulin levels, lactic dehydrogenase, and beta 2 microglobulin. 8,12,13,17,23,24 Results…”

Section: Methods and Casesmentioning

confidence: 99%

“…19 Although approved for treatment of erythrodermic patients (T4 skin rating), ECP has also produced remissions in patients with clinically early MF and with tumor phase disease. 10,12,15,[19][20][21] The addition of biological response modifiers, such as interferon a, granulocyte macrophage colony stimulating factor (GM-CSF), and retinoids, to ECP has been shown to result in higher response rates as reviewed by Rook et al 11,22,23 Gottlieb et al 11 reported a ten-year experience at the University of Pennsylvania using ECP alone and in combination with rIFN-a. 11 Thirty-one of the 41 patients with CTCL who received more than six months of photopheresis therapy had evaluable disease.…”

mentioning

confidence: 99%

Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma

Duvic

Chiao

Talpur

2003

Journal of Cutaneous Medicine and Surgery: Incorporating Medica

View full text Add to dashboard Cite

Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment

Cited by 12 publications

References 0 publications

Narrow‐band ultraviolet B decreases serum interleukin‐2 receptor levels in patients with poikiloderma vasculare atrophicans

Narrow‐band ultraviolet B decreases serum interleukin‐2 receptor levels in patients with poikiloderma vasculare atrophicans

Peripheral Blood Immunological Parameters for Use as Markers of Pre-invasive to Invasive Colorectal Cancer

Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About